Last update 01 Nov 2024

Cav2.2 x SERT x CACNA2D2

Basic Info

Related Targets
Cav2.2SERTCACNA2D2

Related

1
Drugs associated with Cav2.2 x SERT x CACNA2D2
Trazodone/Gabapentin
Target
CACNA2D2 x Cav2.2 x SERT
Mechanism
CACNA2D2 blockers [+2]
Active Org.-
Originator Org.
Angelini Pharma, Inc.
Active Indication-
Inactive Indication
Diabetic Neuropathies
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with Cav2.2 x SERT x CACNA2D2
NCT03749642 / CompletedPhase 2
Efficacy and Safety of Fixed-Dose Combination (FDC) Products Containing Trazodone and Gabapentin in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose Finding Study.
100 Clinical Results associated with Cav2.2 x SERT x CACNA2D2
Login to view more data
100 Translational Medicine associated with Cav2.2 x SERT x CACNA2D2
Login to view more data
0 Patents (Medical) associated with Cav2.2 x SERT x CACNA2D2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free